Quince Therapeutics
(NASDAQ) QNCX
Quince Therapeutics Financials at a Glance
Market Cap
$17.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$33.04M
EPS (TTM)
-$182.05
P/E Ratio
-0.10
Dividend
$0.00
Beta (Volatility)
1.24 (Average)
Dividend
$0.00
Beta (Volatility)
1.24 (Average)
Price
$17.56
Volume
10,097
Open
$17.58
Price
$17.56
Volume
10,097
Open
$17.58
Previous Close
$17.25
Daily Range
$16.90 - $17.84
52-Week Range
$15.10 - $909.98
Estimated Earnings Date
Aug 11, 2026
Dividend
$0.00
Beta (Volatility)
1.24 (Average)
Price
$17.56
Volume
10,097
Open
$17.58
Previous Close
$17.25
Daily Range
$16.90 - $17.84
52-Week Range
$15.10 - $909.98
Estimated Earnings Date
Aug 11, 2026
QNCX News
Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Quince Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
38
CEO
Dirk Thye, MD
Website
quincetx.comHeadquarters
South San Francisco, CA 94080, US
QNCX Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
1823.49%
Return on Capital
N/A
Return on Assets
-124.09%
Earnings Yield
-10.00%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$17.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
978.00K
Volume
10.10K
Avg. Volume
184.30K
Financials (TTM)
Gross Profit
-$71.00K
Operating Income
-$53.79M
EBITDA
-$12.86M
Operating Cash Flow
-$39.45M
Capital Expenditure
-$204.00K
Free Cash Flow
-$39.66M
Cash & ST Invst.
$18.16M
Total Debt
$406.00K
Quince Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$36.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$17.11MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$475.40K
N/A
Employees
36
N/A
Net Income
$35.91M
+338.9%
EBITDA
$30.61M
+337.2%
Quarterly Fundamentals
Total Cash
$18.16M
-42.5%
Total Debt
$406.00K
-97.4%
Accounts Receivable
$5.27M
+475.7%
Inventory
$0.00
N/A
Long Term Debt
$293.00K
-98.1%
Short Term Debt
$113.00K
+10.8%
Return on Assets
-1.24%
N/A
Return on Invested Capital
-3.01%
N/A
Free Cash Flow
-$7.63M
+21.8%
Operating Cash Flow
-$7.63M
+20.6%